Speaker Profile
M.D., Director, U. of Utah
Biography
Dr Kohli's academic journey as a physician and physician-scientist over the past 24 years has centered on multi-disciplinary teams that deliver convergence science-based solutions to enhance cancer care. He has worked in NCI-designated comprehensive cancer care matrix centers, tertiary-level VA facilities, university settings, and not-for-profit clinics, gaining a deep understanding of the complexities inherent in each care model. Currently, he holds the position of tenured Professor in the Department of Medicine and the Jack and Hazel Robertson Presidential Endowed Chair at the University of Utah-Huntsman Cancer Institute in cancer research. As a clinician-scientist his multi-disciplinary teams focus has secured continuous and multiple NIH RO1 grant funding since 2011.He develops real-world annotated biobanks to apply the rapid advances in computing power to develop patented algorithms through in silico multi-omic, machine learning modeling for clinical applications that can results in developing innovative biomarker-based enrichment-type clinical trial designs for enhancing individualized care in cancer.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Klaus Pantel, University Medical Center Hamburg-Eppendorf / ELBS
• Daniel De Carvalho, University of Toronto
Keynote: Early Detection of Cancer by Multimodal Liquid Biopsy Analysis
• Klaus Pantel, UKE / ELBS
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Manel Esteller, Sant Pau Research Institute
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Klaus Pantel, UKE / ELBS
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Luis Diaz, MSKCC
• Eric Klein, GRAIL
• Peter Bach, DELFI Diagnostics
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Matthew Baker, Dxcover
• Pankaj Vats, NVIDIA
Fragmentomics for Early Detection
• Varsha Rao, Claret Bioscience
Integrating Genetic Risk with Early Detection
• Giordano Botta, Allelica
Metagenomic Diagnostics & Global Pathogen Surveillance
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection
• Atul Sharan, CellMax Life
AI-Enhanced Proteomic Signatures for Early Cancer Detection
• Diana Abdueva, Aqtual
